Major Estimate Revision • May 26
Consensus EPS estimates increase by 31% The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from د.إ30.2b to د.إ31.2b. EPS estimate increased from د.إ0.135 to د.إ0.178 per share. Net income forecast to grow 10% next year vs 16% growth forecast for Healthcare industry in United Arab Emirates. Consensus price target broadly unchanged at د.إ4.03. Share price rose 3.3% to د.إ2.19 over the past week. Major Estimate Revision • May 19
Consensus EPS estimates fall by 33% The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from د.إ31.3b to د.إ30.2b. EPS estimate also fell from د.إ0.203 per share to د.إ0.135 per share. Net income forecast to shrink 2.9% next year vs 16% growth forecast for Healthcare industry in United Arab Emirates . Consensus price target of د.إ4.04 unchanged from last update. Share price was steady at د.إ2.11 over the past week. Upcoming Dividend • Apr 03
Upcoming dividend of د.إ0.054 per share Eligible shareholders must have bought the stock before 10 April 2026. Payment date: 08 May 2026. Payout ratio is a comfortable 19% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of Emirian dividend payers (7.1%). Lower than average of industry peers (2.0%). Announcement • Mar 23
Pure Health Holding PJSC(ADX:PUREHEALTH) dropped from FTSE All-World Index (USD) Pure Health Holding PJSC(ADX:PUREHEALTH) dropped from FTSE All-World Index (USD) Declared Dividend • Mar 14
Dividend increased to د.إ0.054 Dividend of د.إ0.054 is 75% higher than last year. Ex-date: 10th April 2026 Payment date: 8th May 2026 Dividend yield will be 2.4%, which is higher than the industry average of 1.7%. Payout Ratios Payout ratio: 19%. Cash payout ratio: 9%. Major Estimate Revision • Feb 16
Consensus EPS estimates fall by 20% The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from د.إ32.0b to د.إ31.3b. EPS estimate also fell from د.إ0.223 per share to د.إ0.18 per share. Net income forecast to shrink 0.4% next year vs 19% growth forecast for Healthcare industry in United Arab Emirates . Consensus price target broadly unchanged at د.إ4.09. Share price fell 2.2% to د.إ2.69 over the past week. Announcement • Feb 10
Pure Health Holding PJSC Proposes to Distribute A Cash Dividend for Fiscal Year 2025 Pure Health Holding PJSC proposed to distribute a cash dividend of USD 163 million for fiscal year 2025, subject to regulatory and shareholder approvals. Reported Earnings • Feb 10
Full year 2025 earnings: EPS in line with expectations, revenues disappoint Full year 2025 results: EPS: د.إ0.18 (up from د.إ0.15 in FY 2024). Revenue: د.إ27.3b (up 5.7% from FY 2024). Net income: د.إ2.00b (up 17% from FY 2024). Profit margin: 7.3% (up from 6.6% in FY 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 9.6% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare industry in Asia. Valuation Update With 7 Day Price Move • Jan 22
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to د.إ2.87, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 18x in the Healthcare industry in Asia. Total loss to shareholders of 19% over the past year. Announcement • Jan 01
Purehealth Introduces Pilot Phase of "Nada", an Ai-Based Tool to Assist Doctors in Documenting Medical Notes During Patient Visits PureHealth has announced the launch of the pilot phase of "Nada", an AI-powered service that functions as a secure digital assistant, supporting physicians by capturing and organising clinical notes from medical conversations in real time. The pilot has been rolled out across selected PureHealth healthcare facilities as part of the Group's efforts to enhance patient experience and improve the documentation and understanding of clinical information, through the deployment of advanced artificial intelligence technologies within a framework that prioritises patient privacy, data security, and compliance with relevant regulatory standards in the Emirate. Developed specifically for use during clinical consultations, "Nada" enables physicians to focus fully on patients' needs, in line with a human-centred model of care that responds to even the most nuanced requirements. At the same time, the service reduces the need for manual notetaking and documentation during consultations, while ensuring that medical records remain accurate, comprehensive, and clinically reliable. The pilot phase of "Nada" follows a rigorous, multi-phase evaluation and testing process conducted across SEHA's hospital network in the UAE. This included high-volume primary care settings, specialised services, and advanced, complex tertiary hospital environments. The pilot phase will enable physicians and healthcare providers using "Nada" to reduce the time spent on clinical documentation by more than 50%, reclaiming an average of over two hours per clinician per day for direct patient care. The technology is also distinguished by its high levels of accuracy in capturing complex medical terminology and local dialects, supporting more precise clinical documentation and improving the quality and continuity of patients' medical records. For patients, the benefits are tangible and immediate. Consultations become more personal and less transactional, with doctors able to maintain eye contact, listen more closely and engage more meaningfully. Patients experience clearer communication, fewer repeated explanations and greater confidence that their concerns, symptoms and care plans are accurately reflected throughout their healthcare journey. By integrating ambient AI that listens only within the clinical consultation and structures medical information instantly, PureHealth is moving beyond traditional digitisation towards a new era of cognitive healthcare, where technology operates quietly in the background to support people rather than replace them. The name "Nada" carries particular resonance in Arabic, where it is associated with gentle presence,iveness and calm clarity. In a healthcare context, it reflects the principle of being truly heard, a value that sits at the heart of PureHealth's approach to patient-centred care. Through "Nada", PureHealth is demonstrating how advanced artificial intelligence can be responsibly embedded into clinical practice to enhance patient experience, strengthen healthcare systems and deliver meaningful, long-term impact for communities. Reported Earnings • Nov 04
Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2025 results: EPS: د.إ0.05 (up from د.إ0.039 in 3Q 2024). Revenue: د.إ6.53b (up 1.2% from 3Q 2024). Net income: د.إ520.8m (up 21% from 3Q 2024). Profit margin: 8.0% (up from 6.7% in 3Q 2024). Revenue missed analyst estimates by 10%. Earnings per share (EPS) exceeded analyst estimates by 16%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare industry in Asia. Announcement • Oct 28
Pure Health Holding PJSC to Report Q3, 2025 Results on Oct 31, 2025 Pure Health Holding PJSC announced that they will report Q3, 2025 results on Oct 31, 2025 Reported Earnings • Aug 01
Second quarter 2025 earnings released: EPS: د.إ0.05 (vs د.إ0.046 in 2Q 2024) Second quarter 2025 results: EPS: د.إ0.05 (up from د.إ0.046 in 2Q 2024). Revenue: د.إ6.99b (up 9.5% from 2Q 2024). Net income: د.إ522.3m (up 1.8% from 2Q 2024). Profit margin: 7.5% (down from 8.0% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.6% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare industry in Asia. Announcement • Jul 25
Pure Health Holding PJSC to Report Q2, 2025 Results on Jul 30, 2025 Pure Health Holding PJSC announced that they will report Q2, 2025 results on Jul 30, 2025 Price Target Changed • Jun 17
Price target decreased by 9.9% to د.إ4.19 Down from د.إ4.65, the current price target is an average from 4 analysts. New target price is 72% above last closing price of د.إ2.44. Stock is down 43% over the past year. The company is forecast to post earnings per share of د.إ0.21 for next year compared to د.إ0.15 last year. Reported Earnings • May 02
First quarter 2025 earnings released: EPS: د.إ0.05 (vs د.إ0.044 in 1Q 2024) First quarter 2025 results: EPS: د.إ0.05 (up from د.إ0.044 in 1Q 2024). Revenue: د.إ6.58b (up 7.6% from 1Q 2024). Net income: د.إ503.8m (up 2.9% from 1Q 2024). Profit margin: 7.7% (down from 8.0% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.6% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare industry in Asia. Announcement • Apr 16
Pure Health Holding PJSC Appoints H.E. Kamal Ishaq Abdullah Ismail Al Maazmi, as the Chairman of the Board of Directors Pure Health Holding PJSC announced that at the board meeting held on 15 April, 2025 approved election of the H.E. Kamal Ishaq Abdullah Ismail Al Maazmi, as the chairman of the board of directors of the company. Buy Or Sell Opportunity • Apr 07
Now 24% undervalued after recent price drop Over the last 90 days, the stock has fallen 27% to د.إ2.52. The fair value is estimated to be د.إ3.30, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 58% over the last year. Earnings per share has grown by 60%. For the next 3 years, revenue is forecast to grow by 9.0% per annum. Earnings are also forecast to grow by 21% per annum over the same time period. Announcement • Jan 28
Pure Health Holding PJSC (ADX:PUREHEALTH) agreed to acquire 60% stake in Hellenic Healthcare Group from CVC European Equity Partners VI LP a fund managed by CVC Capital Partners plc (ENXTAM:CVC) and founder of HHG in a transaction valued at $2.3 billion. Pure Health Holding PJSC (ADX:PUREHEALTH) agreed to acquire 60% stake in Hellenic Healthcare Group from CVC European Equity Partners VI LP a fund managed by CVC Capital Partners plc (ENXTAM:CVC) and founder of HHG in a transaction valued at $2.3 billion on January 27, 2025. Under the terms of agreement, PureHealth will acquire a 60% stake in HHG, with CVC Capital Partners retaining 35% ownership, while the remaining 5% stake in the company is held by the founder i.e., following completion of the transaction, CVC Capital Partners VI and HHG Management will retain a 40% stake in HHG, continuing as a strategic partners to support the Company's growth and transformation. As a part of acquisition, PureHealth and CVC will collaborate closely, combining their expertise to expand HHG into a larger organisation. The closing of the transaction is subject to regulatory approvals and customary closing conditions. Price Target Changed • Jan 10
Price target decreased by 10% to د.إ5.33 Down from د.إ5.95, the current price target is an average from 3 analysts. New target price is 51% above last closing price of د.إ3.53. Stock is down 33% over the past year. The company is forecast to post earnings per share of د.إ0.19 for next year compared to د.إ0.096 last year. Board Change • Dec 31
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Non Executive Non Independent Vice Chairman Hamad Salem Binlouteya Alameri is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • Nov 14
NMC Reportedly Going to Be Bought by PureHealth Nmc Specialty Hospitals could soon have a new owner, with Pure Health Holding PJSC (ADX:PUREHEALTH) name being suggested in what could be one of the UAE’s biggest corporate takeovers. If the deal happens – and banking sources say it’s more or less a ‘done one’ – NMC could come under PureHealth’s ownership at some point in 2025. PureHealth has not responded to queries related to the NMC takeover as of this moment. PureHealth will get a network of hospitals that are ‘operating at peak capacity’ and is ‘profitable’, according to banking industry sources. NMC will finally find an anchor. But it will be NMC that will, if the deal goes through, find closure after over 3 years of turmoil and calmer waters since March 2022, when lenders and creditors led by ADCB took over the operations and worked to turn it around. Reported Earnings • Nov 02
Third quarter 2024 earnings released: EPS: د.إ0.039 (vs د.إ0.008 loss in 3Q 2023) Third quarter 2024 results: EPS: د.إ0.039 (up from د.إ0.008 loss in 3Q 2023). Revenue: د.إ6.45b (up 63% from 3Q 2023). Net income: د.إ430.5m (up د.إ506.6m from 3Q 2023). Profit margin: 6.7% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 10.0% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare industry in Asia. Reported Earnings • Aug 03
Second quarter 2024 earnings released: EPS: د.إ0.046 (vs د.إ0.008 loss in 2Q 2023) Second quarter 2024 results: EPS: د.إ0.046 (up from د.إ0.008 loss in 2Q 2023). Revenue: د.إ6.39b (up 61% from 2Q 2023). Net income: د.إ513.1m (up د.إ589.1m from 2Q 2023). Profit margin: 8.0% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare industry in Asia. Valuation Update With 7 Day Price Move • Jun 11
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to د.إ4.31, the stock trades at a trailing P/E ratio of 38.7x. Average trailing P/E is 24x in the Healthcare industry in Asia. Buy Or Sell Opportunity • Jun 10
Now 21% overvalued The stock has been flat over the last 90 days, currently trading at د.إ3.99. The fair value is estimated to be د.إ3.29, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 35% over the last year. Earnings per share has declined by 64%. Reported Earnings • May 05
First quarter 2024 earnings released: EPS: د.إ0.044 (vs د.إ0.12 in 1Q 2023) First quarter 2024 results: EPS: د.إ0.044 (down from د.إ0.12 in 1Q 2023). Revenue: د.إ6.12b (up 47% from 1Q 2023). Net income: د.إ489.5m (down 59% from 1Q 2023). Profit margin: 8.0% (down from 29% in 1Q 2023).